Characteristics of patients treated with CBT
Patient . | Gender . | Age(y) . | Diagnosis . | Platelets (×109/L) . | Neutrophils (×109/L) . | Axial ABMvolume(ml/kg IBW) . | AppendicularABM volume(ml/kg IBW) . | Disease status . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 30 . | Day 60 . | Day 100 . | Day 30 . | Day 60 . | Day 100 . | |||||||
1 | M | 63 | NHL | 10 | 16 | 54 | 0.1 | 3.4 | 2.6 | 6.00 | 2.68 | PR |
2 | F | 34 | AML | 10 | 33 | 19 | 1.5 | 7.8 | 5.3 | 4.5 | 0.05 | CR |
3 | F | 47 | AML | 15 | 73 | 115 | 3.8 | 3.0 | 4.3 | 4.4 | 0.11 | CR |
4 | M | 45 | AML | 30 | 99 | 125 | 0.6 | 2.0 | 5.4 | 3.32 | 2.23 | CR |
5 | M | 21 | ALL | 15 | 65 | 70 | 1.2 | 3.7 | 4.1 | 5.62 | 0.25 | CR |
6 | M | 44 | AML | 19 | 75 | 126 | 6.4 | 3.5 | 5.8 | 6.17 | 0.25 | CR |
7 | M | 35 | ALL | 70 | 212 | 54 | 6.3 | 2.7 | 19.6 | 5.63 | 0.49 | CR |
8 | M | 31 | NHL | 12 | 15 | 46 | 5.4 | 6.2 | 4.2 | 4.83 | 0.35 | CR |
9 | F | 30 | MM | 43 | 187 | 170 | 3.5 | 10.8 | 4.0 | 4.58 | 0.01 | CR |
10 | M | 49 | ALL | 14 | 90 | 129 | 1.5 | 3.8 | 2.6 | 6.49 | 0.79 | CR |
11 | M | 43 | AML | 19 | 81 | 97 | 1.0 | 2.5 | 1.8 | 4.19 | 0.26 | CR |
12 | F | 22 | AML | 41 | 144 | 97 | 3.2 | 7.2 | 3.4 | 4.99 | 2.04 | CR |
13 | M | 35 | ALL | 22 | 87 | 97 | 0.1 | 6.6 | 5.5 | 5.32 | 0.32 | CR |
14 | M | 53 | AML | 19 | 77 | 143 | 1.9 | 4.1 | 8.1 | 3.47 | 2 36 | CR |
15 | M | 56 | AML | 9 | 33 | 48 | 0.3 | 11.0 | 7.2 | 5.04 | 0.74 | CR |
16 | M | 46 | MM | 10 | 139 | 167 | 0.9 | 10.5 | 9.3 | 4.06 | 1.29 | CR |
Mean | 41 | 23 ± 16 | 89 ± 57 | 98 ± 45 | 2.4 ± 2.1 | 5.6 ± 3.2 | 5.6 ± 4.4 | 4.9 ± 0.9 | 0.9 ± 0.9 | 15/16 CR | ||
P vs ACT | NS | <.01 | <.05 | <.05 | <.05 | NS | NS | NS | <.05 | NS |
Patient . | Gender . | Age(y) . | Diagnosis . | Platelets (×109/L) . | Neutrophils (×109/L) . | Axial ABMvolume(ml/kg IBW) . | AppendicularABM volume(ml/kg IBW) . | Disease status . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 30 . | Day 60 . | Day 100 . | Day 30 . | Day 60 . | Day 100 . | |||||||
1 | M | 63 | NHL | 10 | 16 | 54 | 0.1 | 3.4 | 2.6 | 6.00 | 2.68 | PR |
2 | F | 34 | AML | 10 | 33 | 19 | 1.5 | 7.8 | 5.3 | 4.5 | 0.05 | CR |
3 | F | 47 | AML | 15 | 73 | 115 | 3.8 | 3.0 | 4.3 | 4.4 | 0.11 | CR |
4 | M | 45 | AML | 30 | 99 | 125 | 0.6 | 2.0 | 5.4 | 3.32 | 2.23 | CR |
5 | M | 21 | ALL | 15 | 65 | 70 | 1.2 | 3.7 | 4.1 | 5.62 | 0.25 | CR |
6 | M | 44 | AML | 19 | 75 | 126 | 6.4 | 3.5 | 5.8 | 6.17 | 0.25 | CR |
7 | M | 35 | ALL | 70 | 212 | 54 | 6.3 | 2.7 | 19.6 | 5.63 | 0.49 | CR |
8 | M | 31 | NHL | 12 | 15 | 46 | 5.4 | 6.2 | 4.2 | 4.83 | 0.35 | CR |
9 | F | 30 | MM | 43 | 187 | 170 | 3.5 | 10.8 | 4.0 | 4.58 | 0.01 | CR |
10 | M | 49 | ALL | 14 | 90 | 129 | 1.5 | 3.8 | 2.6 | 6.49 | 0.79 | CR |
11 | M | 43 | AML | 19 | 81 | 97 | 1.0 | 2.5 | 1.8 | 4.19 | 0.26 | CR |
12 | F | 22 | AML | 41 | 144 | 97 | 3.2 | 7.2 | 3.4 | 4.99 | 2.04 | CR |
13 | M | 35 | ALL | 22 | 87 | 97 | 0.1 | 6.6 | 5.5 | 5.32 | 0.32 | CR |
14 | M | 53 | AML | 19 | 77 | 143 | 1.9 | 4.1 | 8.1 | 3.47 | 2 36 | CR |
15 | M | 56 | AML | 9 | 33 | 48 | 0.3 | 11.0 | 7.2 | 5.04 | 0.74 | CR |
16 | M | 46 | MM | 10 | 139 | 167 | 0.9 | 10.5 | 9.3 | 4.06 | 1.29 | CR |
Mean | 41 | 23 ± 16 | 89 ± 57 | 98 ± 45 | 2.4 ± 2.1 | 5.6 ± 3.2 | 5.6 ± 4.4 | 4.9 ± 0.9 | 0.9 ± 0.9 | 15/16 CR | ||
P vs ACT | NS | <.01 | <.05 | <.05 | <.05 | NS | NS | NS | <.05 | NS |
CR, complete response; F, female; M, male; NS, not significant; PR, partial response.